- Trial phase
- Phase 2/3
- Time to market
- Enrollment in the pivotal AMPLITUDE trial is complete. The next gateway is the interim analysis expected in early 2027. If positive, Vertex says it could support a US accelerated approval filing. A first approval is unlikely before 2028 given the filing and FDA review timeline.
- Why 5/10
- The next hard, dated catalyst is the AMPLITUDE Phase 2/3 interim analysis expected in early 2027 (roughly 4-6 months from today). This is a pivotal readout on a drug with first-in-class potential and blockbuster sales estimates, but Vertex is a diversified large-cap with a ~$140B market cap, a massive cystic fibrosis franchise, and multiple other pipeline priorities including a PDUFA for povetacicept on November 30, 2026. Inaxaplin is an important pipeline asset but not the sole or dominant value driver for the company, capping the impact score at 5.
Watch for the AMPLITUDE Phase 2/3 interim analysis readout expected in early 2027. Positive data showing statistically significant eGFR benefit or proteinuria reduction at 48 weeks could trigger an accelerated approval filing and a meaningful stock move upward. A miss or equivocal result would eliminate the accelerated pathway and likely pressure the stock as the program faces a multi-year delay for a full Phase 3 readout. Vertex also reports Q3 2026 earnings today (November 2, 2026), which may include pipeline updates on inaxaplin's regulatory timeline.
Price Chart
Executive Summary
Inaxaplin (VX-147) is Vertex Pharmaceuticals' oral small-molecule APOL1 inhibitor in development for APOL1-mediated kidney disease (AMKD), a genetic kidney condition with no approved therapies. Phase 2b data showed a 42.7% reduction in proteinuria in a broader AMKD population, supporting expansion beyond the severe-proteinuria cohort enrolled in the pivotal AMPLITUDE trial. The global Phase 2/3 AMPLITUDE study has completed enrollment, and its pre-planned interim analysis in early 2027 is the next major catalyst. Vertex has FDA Breakthrough Therapy and EMA PRIME designations. For Vertex, a large-cap biotech (~$140B market cap) with a dominant cystic fibrosis franchise and numerous pipeline programs, inaxaplin is a meaningful but not dominant value driver. The rating reflects the drug's first-in-class potential balanced against the program's mid-stage status, the open-label nature of Phase 2b data, and the fact that the key binary readout is still months away.
How It Works
Inaxaplin is an oral pill that blocks the activity of a protein called APOL1. In some people of African ancestry, genetic variants of APOL1 cause the protein to form holes in kidney cell membranes, leading to progressive kidney damage and protein leaking into the urine. By inhibiting this channel function, inaxaplin aims to treat the root cause of APOL1-mediated kidney disease (AMKD).
Trial Status
Phase 2a proof-of-concept in 16 patients was published in the New England Journal of Medicine showing a mean 47.6% reduction in proteinuria. Phase 2b AMPLIFIED study (NCT06794996, 42 patients) completed with positive topline results announced September 22, 2026: a 42.7% reduction in UACR at Week 13 vs baseline in the modest-proteinuria cohort, and a 17.3% reduction (95% CI crossing zero) in the AMKD-plus-type-2-diabetes cohort. The global Phase 2/3 AMPLITUDE pivotal trial (NCT05312879) has completed enrollment and is blinded with a 45 mg once-daily oral dose vs placebo on top of standard of care. The pre-planned interim analysis is expected after the IA cohort reaches 48 weeks of treatment.
The Two-Sided Case
Upcoming Catalysts
- AMPLITUDE Phase 2/3 interim analysis results in early 2027 -- positive data could support an accelerated approval filing with the FDA; negative data would materially delay the program
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VERTEX PHARMACEUTICALS INC / MA 8-K VRTX ·Originating report